• Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens
  • A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas
  • AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount
  • Dividend Investing Newsletter and model portfolio that focuses on dividend growth
  • AAII Growth Investing Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.
  • Retirement Investing Discover trusted strategies for every stage of retirement. Get actionable insights and resources for smart retirement planning.
  • Sentiment Investing A research-driven newsletter with 10+ signals decoding sentiment across retail and institutional behavior.
  • Stock Superstars Report Get stock ideas inspired by the market's leading professionals
  • VMQ Stocks For the value investor looking to harness academic research in an actively managed portfolio
  • Bits and Bips Newsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Explore All Membership Options
Join Now

Stock Evaluator: Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. CRBP

$6.82 0.19 2.87%
September 30, 2026 4:00:00 PM EST November 10, 2021 Volume: 506,988
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Commentary & Analysis

Financial Summary

Share Statistics CRBP Industry
Median		 Percentile
(All Stocks)
Market Cap (Mil) $131.7 $257.1 24%
Shares Out (Mil) 19.4 54.0 30%
Institutional Ownership 99.1% 93.2% 85%
Float (Mil) 15.2 41.3 25%
Beta 2.64 0.95 97%
Avg Daily Volume (000s) 758 728 63%
Price Change
(52-week)		 (44.5%) 50.6% 20%
Growth CRBP Industry
Median		 Percentile
(All Stocks)
Sales (5yr) na 12.8% na
Net Income (5yr) 6.7% (10.1%) 50%
EPS (5yr) 32.7% 15.7% 83
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (47.3%) (15.7%) 8%
Estimates Qtrly Current
Fiscal
Year		 Next
Fiscal
Year
# of Estimates 10 10 9
Current EPS ($1.214) ($5.434) ($5.513)
Month Ago EPS ($1.214) ($5.434) ($5.513)
# Rev Up 1 0 1
# Rev Down 0 1 1
Three Months Ago EPS ($1.034) ($4.565) ($5.076)
Year/Year Chg (32.7%) (7.9%) (3.0%)
Financials CRBP Industry
Median		 Percentile
(All Stocks)
Sales (TTM) (Mil) na $37 na
Net Income (TTM) (Mil) ($102) ($44) 11%
EPS (TTM) ($6.089) ($1.600) 7%
Operating Cash Flow (TTM) (Mil) ($87) ($33) 7%
Net Cash Flow (TTM) (Mil) na $2 na
Long-Term Debt (Q1) (Mil) $3 $4 22%
Enterprise Value (Q1) (Mil) $31 $173 13%
Valuation CRBP Industry
Median		 Percentile
(All Stocks)
P/B 1.24 2.52 33%
P/E na 19.4 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.0 na
Ratios CRBP Industry
Median		 Percentile
(All Stocks)
Gross Margin na 68.2% na
Net Margin na (73.7%) na
ROA (80.9%) (47.7%) 7%
ROE (95.6%) (54.9%) 9%
Liabilities to Assets 19.5% 29.0% 13%
F-Score 1 3 1%

Corbus Pharmaceuticals Holdings, Inc. did not pass any screens on 9/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors